The latest domestic price trend of ceritinib in 2025

Ceritinib is a highly targeted ALK inhibitor specifically designed to treat patients with ALK rearrangement-positive metastatic non-small cell lung cancer (NSCLC). The ALK fusion gene is a driver mutation. Although it only accounts for about 3%-5% of NSCLC patients, it is more common in young adenocarcinoma patients with no history of smoking. This group of people has poor response to chemotherapy or immunotherapy and is therefore highly dependent on ALK-targeted drugs. CeritinibAs a second-generation ALK inhibitor, it has shown good tumor shrinkage and prolonged median progression-free survival in patients who failed crizotinib treatment.

ExceptNSCLC, there is currently no clear expanded indication approved in the country. However, in overseas studies, ceritinib has also been tried to be used in ROS1-positive lung cancer and some other ALK-positive solid tumors, and the results are still in the clinical exploration stage. In the domestic approved label, its indications are mainly focused on adults with ALK-positive metastatic NSCLC who have previously received crizotinib treatment and have progressed, or who are intolerant to crizotinib.

In China, ceritinib has been introduced and marketed by Novartis under the trade name"Zykadia". With the dynamic adjustment of the medical insurance catalog in recent years, this drug has been included in the national medical insurance catalog, significantly reducing the burden on patients. According to the market reference price before medical insurance reimbursement, the common packaging of ceritinib is 150 mg × 150 tablets, with the price ranging from RMB 13,000 to RMB 16,000. The price after inclusion in medical insurance varies according to specific provincial and municipal policies, and the out-of-pocket ratio varies.

Since this drug is a prescription drug and its use must strictly follow the instructions of a doctor, patients can obtain the qualification to prescribe it in the oncology department or respiratory department of domestic hospitals. The hospital may also be equipped with genetic testing services to determine whether there is an abnormality in the ALK gene to determine whether it is appropriate to use ceritinib. WithoutALK mutation, blind medication is not only ineffective, but may also increase the risk of side effects. Therefore, accurate gene typing is a key step in medication.

Reference materials:https://go.drugbank.com/drugs/DB09063